(PHGE) – Company Press Releases
-
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infecti
-
BiomX Announces the Appointment of Susan Blum to its Board of Directors
-
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
-
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
-
Telum Therapeutics appoints Dr. Subhendu Basu as CEO
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fi
-
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections
-
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
-
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
-
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North
-
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
-
BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
-
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respirat
-
BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
-
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
-
NYSE American Initiates Delisting Proceedings for BiomX Warrants
-
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Scie
-
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
-
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
-
BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023
-
BiomX Announces Second Closing of $7.5 Million Private Placement
-
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
-
BiomX Announces $7.5 Million Private Placement
-
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
-
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
-
BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
-
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
-
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
-
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
-
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
-
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
-
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
-
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
-
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
-
BiomX Announces Corporate Restructuring
-
BiomX Announces Publication in the Journal, Bioinformatics
-
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
-
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
-
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
-
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
-
BiomX Presenting at Three Upcoming Investor Conferences
-
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
-
BiomX Presenting at Two Upcoming Conferences in November
-
BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update
Back to PHGE Stock Lookup
